Frovatriptan-d3 succinate(Synonyms: (R)-Frovatriptan-d3 succinate; SB 209509-d3 succinate; VML 251-d3 succinate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Frovatriptan-d3 succinate (Synonyms: (R)-Frovatriptan-d3 succinate; SB 209509-d3 succinate; VML 251-d3 succinate)

Frovatriptan-d3 (succinate) 是 Frovatriptan (succinate) 氘代物。Frovatriptan succinate ((R)-Frovatriptan succinate) 是一种强效，高亲和力，选择性和具有口服活性的 5-HT1B (pK50 为 8.2) 和 5-HT1D 受体激动剂，选择性是 5-HT1A，5-HT1F 和 5-HT7 的 10 倍以上，是其他 5-HT，多巴胺，组胺 H1 和 α1-肾上腺素受体的 1000 倍以上。Frovatriptan succinate 可用于偏头痛的研究。

Frovatriptan-d3 succinate(Synonyms: (R)-Frovatriptan-d3 succinate; SB 209509-d3 succinate; VML 251-d3 succinate)

Frovatriptan-d3 succinate Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Frovatriptan-d3 (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

364.41

Formula

C18H20D3N3O5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Kelman L. Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat. 2008 Feb;4(1):49-54.

    [3]. Comer MB. Et al. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache. 2002 Apr;42 Suppl 2:S47-53.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务